|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:ITPR2-KRAS (FusionGDB2 ID:40702) |
Fusion Gene Summary for ITPR2-KRAS |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: ITPR2-KRAS | Fusion gene ID: 40702 | Hgene | Tgene | Gene symbol | ITPR2 | KRAS | Gene ID | 3709 | 3845 |
| Gene name | inositol 1,4,5-trisphosphate receptor type 2 | KRAS proto-oncogene, GTPase | |
| Synonyms | ANHD|CFAP48|INSP3R2|IP3R2 | 'C-K-RAS|C-K-RAS|CFC2|K-RAS2A|K-RAS2B|K-RAS4A|K-RAS4B|K-Ras|K-Ras 2|KI-RAS|KRAS1|KRAS2|NS|NS3|OES|RALD|RASK2|c-Ki-ras|c-Ki-ras2 | |
| Cytomap | 12p11.23 | 12p12.1 | |
| Type of gene | protein-coding | protein-coding | |
| Description | inositol 1,4,5-trisphosphate receptor type 2IP3 receptorIP3R 2cilia and flagella associated protein 48type 2 InsP3 receptor | GTPase KRasK-ras p21 proteinKirsten rat sarcoma viral oncogene homologKirsten rat sarcoma viral proto-oncogenePR310 c-K-ras oncogenec-Kirsten-ras proteincellular c-Ki-ras2 proto-oncogenecellular transforming proto-oncogeneoncogene KRAS2transformi | |
| Modification date | 20200313 | 20200329 | |
| UniProtAcc | . | P01116 | |
| Ensembl transtripts involved in fusion gene | ENST00000381340, ENST00000242737, ENST00000545902, | ENST00000256078, ENST00000556131, ENST00000557334, ENST00000311936, | |
| Fusion gene scores | * DoF score | 21 X 18 X 10=3780 | 6 X 6 X 4=144 |
| # samples | 23 | 7 | |
| ** MAII score | log2(23/3780*10)=-4.03868046816406 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(7/144*10)=-1.04064198449735 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: ITPR2 [Title/Abstract] AND KRAS [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | ITPR2(26703180)-KRAS(25380346), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | ITPR2 | GO:0001666 | response to hypoxia | 19120137 |
| Fusion gene breakpoints across ITPR2 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene breakpoints across KRAS (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | STAD | TCGA-BR-A4PD-01A | ITPR2 | chr12 | 26703180 | - | KRAS | chr12 | 25380346 | - |
Top |
Fusion Gene ORF analysis for ITPR2-KRAS |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 5CDS-intron | ENST00000381340 | ENST00000256078 | ITPR2 | chr12 | 26703180 | - | KRAS | chr12 | 25380346 | - |
| 5CDS-intron | ENST00000381340 | ENST00000556131 | ITPR2 | chr12 | 26703180 | - | KRAS | chr12 | 25380346 | - |
| 5CDS-intron | ENST00000381340 | ENST00000557334 | ITPR2 | chr12 | 26703180 | - | KRAS | chr12 | 25380346 | - |
| In-frame | ENST00000381340 | ENST00000311936 | ITPR2 | chr12 | 26703180 | - | KRAS | chr12 | 25380346 | - |
| intron-3CDS | ENST00000242737 | ENST00000311936 | ITPR2 | chr12 | 26703180 | - | KRAS | chr12 | 25380346 | - |
| intron-3CDS | ENST00000545902 | ENST00000311936 | ITPR2 | chr12 | 26703180 | - | KRAS | chr12 | 25380346 | - |
| intron-intron | ENST00000242737 | ENST00000256078 | ITPR2 | chr12 | 26703180 | - | KRAS | chr12 | 25380346 | - |
| intron-intron | ENST00000242737 | ENST00000556131 | ITPR2 | chr12 | 26703180 | - | KRAS | chr12 | 25380346 | - |
| intron-intron | ENST00000242737 | ENST00000557334 | ITPR2 | chr12 | 26703180 | - | KRAS | chr12 | 25380346 | - |
| intron-intron | ENST00000545902 | ENST00000256078 | ITPR2 | chr12 | 26703180 | - | KRAS | chr12 | 25380346 | - |
| intron-intron | ENST00000545902 | ENST00000556131 | ITPR2 | chr12 | 26703180 | - | KRAS | chr12 | 25380346 | - |
| intron-intron | ENST00000545902 | ENST00000557334 | ITPR2 | chr12 | 26703180 | - | KRAS | chr12 | 25380346 | - |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000381340 | ITPR2 | chr12 | 26703180 | - | ENST00000311936 | KRAS | chr12 | 25380346 | - | 10952 | 5490 | 417 | 5945 | 1842 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000381340 | ENST00000311936 | ITPR2 | chr12 | 26703180 | - | KRAS | chr12 | 25380346 | - | 0.000176159 | 0.99982387 |
Top |
Fusion Genomic Features for ITPR2-KRAS |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
 |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for ITPR2-KRAS |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr12:26703180/chr12:25380346) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| . | KRAS |
| FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}. | FUNCTION: Ras proteins bind GDP/GTP and possess intrinsic GTPase activity (PubMed:20949621). Plays an important role in the regulation of cell proliferation (PubMed:23698361, PubMed:22711838). Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner (PubMed:24623306). {ECO:0000269|PubMed:20949621, ECO:0000269|PubMed:22711838, ECO:0000269|PubMed:23698361, ECO:0000269|PubMed:24623306, ECO:0000305}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000381340 | - | 37 | 57 | 112_166 | 1691 | 2702.0 | Domain | MIR 1 |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000381340 | - | 37 | 57 | 173_223 | 1691 | 2702.0 | Domain | MIR 2 |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000381340 | - | 37 | 57 | 231_287 | 1691 | 2702.0 | Domain | MIR 3 |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000381340 | - | 37 | 57 | 294_372 | 1691 | 2702.0 | Domain | MIR 4 |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000381340 | - | 37 | 57 | 378_434 | 1691 | 2702.0 | Domain | MIR 5 |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000381340 | - | 37 | 57 | 265_269 | 1691 | 2702.0 | Region | Inositol 1%2C4%2C5-trisphosphate binding |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000381340 | - | 37 | 57 | 507_510 | 1691 | 2702.0 | Region | Inositol 1%2C4%2C5-trisphosphate binding |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000381340 | - | 37 | 57 | 567_569 | 1691 | 2702.0 | Region | Inositol 1%2C4%2C5-trisphosphate binding |
| Tgene | KRAS | chr12:26703180 | chr12:25380346 | ENST00000256078 | 1 | 6 | 116_119 | 37 | 333.3333333333333 | Nucleotide binding | GTP | |
| Tgene | KRAS | chr12:26703180 | chr12:25380346 | ENST00000256078 | 1 | 6 | 59_60 | 37 | 333.3333333333333 | Nucleotide binding | GTP | |
| Tgene | KRAS | chr12:26703180 | chr12:25380346 | ENST00000311936 | 1 | 5 | 116_119 | 37 | 189.0 | Nucleotide binding | GTP | |
| Tgene | KRAS | chr12:26703180 | chr12:25380346 | ENST00000311936 | 1 | 5 | 59_60 | 37 | 189.0 | Nucleotide binding | GTP | |
| Tgene | KRAS | chr12:26703180 | chr12:25380346 | ENST00000256078 | 1 | 6 | 166_185 | 37 | 333.3333333333333 | Region | Note=Hypervariable region | |
| Tgene | KRAS | chr12:26703180 | chr12:25380346 | ENST00000311936 | 1 | 5 | 166_185 | 37 | 189.0 | Region | Note=Hypervariable region |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000242737 | - | 1 | 6 | 112_166 | 0 | 182.0 | Domain | MIR 1 |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000242737 | - | 1 | 6 | 173_223 | 0 | 182.0 | Domain | MIR 2 |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000242737 | - | 1 | 6 | 231_287 | 0 | 182.0 | Domain | MIR 3 |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000242737 | - | 1 | 6 | 294_372 | 0 | 182.0 | Domain | MIR 4 |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000242737 | - | 1 | 6 | 378_434 | 0 | 182.0 | Domain | MIR 5 |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000242737 | - | 1 | 6 | 265_269 | 0 | 182.0 | Region | Inositol 1%2C4%2C5-trisphosphate binding |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000242737 | - | 1 | 6 | 507_510 | 0 | 182.0 | Region | Inositol 1%2C4%2C5-trisphosphate binding |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000242737 | - | 1 | 6 | 567_569 | 0 | 182.0 | Region | Inositol 1%2C4%2C5-trisphosphate binding |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000242737 | - | 1 | 6 | 1_2227 | 0 | 182.0 | Topological domain | Cytoplasmic |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000242737 | - | 1 | 6 | 2249_2260 | 0 | 182.0 | Topological domain | Extracellular |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000242737 | - | 1 | 6 | 2282_2307 | 0 | 182.0 | Topological domain | Cytoplasmic |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000242737 | - | 1 | 6 | 2329_2351 | 0 | 182.0 | Topological domain | Extracellular |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000242737 | - | 1 | 6 | 2373_2394 | 0 | 182.0 | Topological domain | Cytoplasmic |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000242737 | - | 1 | 6 | 2416_2521 | 0 | 182.0 | Topological domain | Extracellular |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000242737 | - | 1 | 6 | 2543_2701 | 0 | 182.0 | Topological domain | Cytoplasmic |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000381340 | - | 37 | 57 | 1_2227 | 1691 | 2702.0 | Topological domain | Cytoplasmic |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000381340 | - | 37 | 57 | 2249_2260 | 1691 | 2702.0 | Topological domain | Extracellular |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000381340 | - | 37 | 57 | 2282_2307 | 1691 | 2702.0 | Topological domain | Cytoplasmic |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000381340 | - | 37 | 57 | 2329_2351 | 1691 | 2702.0 | Topological domain | Extracellular |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000381340 | - | 37 | 57 | 2373_2394 | 1691 | 2702.0 | Topological domain | Cytoplasmic |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000381340 | - | 37 | 57 | 2416_2521 | 1691 | 2702.0 | Topological domain | Extracellular |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000381340 | - | 37 | 57 | 2543_2701 | 1691 | 2702.0 | Topological domain | Cytoplasmic |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000242737 | - | 1 | 6 | 2228_2248 | 0 | 182.0 | Transmembrane | Helical |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000242737 | - | 1 | 6 | 2261_2281 | 0 | 182.0 | Transmembrane | Helical |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000242737 | - | 1 | 6 | 2308_2328 | 0 | 182.0 | Transmembrane | Helical |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000242737 | - | 1 | 6 | 2352_2372 | 0 | 182.0 | Transmembrane | Helical |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000242737 | - | 1 | 6 | 2395_2415 | 0 | 182.0 | Transmembrane | Helical |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000242737 | - | 1 | 6 | 2522_2542 | 0 | 182.0 | Transmembrane | Helical |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000381340 | - | 37 | 57 | 2228_2248 | 1691 | 2702.0 | Transmembrane | Helical |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000381340 | - | 37 | 57 | 2261_2281 | 1691 | 2702.0 | Transmembrane | Helical |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000381340 | - | 37 | 57 | 2308_2328 | 1691 | 2702.0 | Transmembrane | Helical |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000381340 | - | 37 | 57 | 2352_2372 | 1691 | 2702.0 | Transmembrane | Helical |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000381340 | - | 37 | 57 | 2395_2415 | 1691 | 2702.0 | Transmembrane | Helical |
| Hgene | ITPR2 | chr12:26703180 | chr12:25380346 | ENST00000381340 | - | 37 | 57 | 2522_2542 | 1691 | 2702.0 | Transmembrane | Helical |
| Tgene | KRAS | chr12:26703180 | chr12:25380346 | ENST00000256078 | 1 | 6 | 32_40 | 37 | 333.3333333333333 | Motif | Note=Effector region | |
| Tgene | KRAS | chr12:26703180 | chr12:25380346 | ENST00000311936 | 1 | 5 | 32_40 | 37 | 189.0 | Motif | Note=Effector region | |
| Tgene | KRAS | chr12:26703180 | chr12:25380346 | ENST00000256078 | 1 | 6 | 10_18 | 37 | 333.3333333333333 | Nucleotide binding | GTP | |
| Tgene | KRAS | chr12:26703180 | chr12:25380346 | ENST00000256078 | 1 | 6 | 29_35 | 37 | 333.3333333333333 | Nucleotide binding | GTP | |
| Tgene | KRAS | chr12:26703180 | chr12:25380346 | ENST00000311936 | 1 | 5 | 10_18 | 37 | 189.0 | Nucleotide binding | GTP | |
| Tgene | KRAS | chr12:26703180 | chr12:25380346 | ENST00000311936 | 1 | 5 | 29_35 | 37 | 189.0 | Nucleotide binding | GTP |
Top |
Fusion Gene Sequence for ITPR2-KRAS |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >40702_40702_1_ITPR2-KRAS_ITPR2_chr12_26703180_ENST00000381340_KRAS_chr12_25380346_ENST00000311936_length(transcript)=10952nt_BP=5490nt CTTCCAGCTCCCGCCGGGCGGCTGTGACGGCCGCAGCGGGTCGCAGAGCAGGGAGTGGACACGGAGTGGGGAGCGGAGAGGGAAGGAGGA GGAGGAGGAGCAAAGGTGTTGGAGAGAAAACTTCAGAAAGGAACAGGAAACCTGCCGGGGAGGCGGCGGCGGCTGCGGCTTCTCTGGGCG CCTGGGCTGCGCTCTTCGCGGGGTGTCCGCAGCTGCGGCTTGGCCCCGGTCTGGCTTCCCCGGCGCGCACGCACGGCTGAGCCGCGACGC TCAGTGGCTCGGGCCGTGCCCTCCGCCGCGGCTCTTGGCCGCTGTAGTCCCGCGATCCGATCCGCTTCTGCCGCGGCGGCTCCCTGGAGA GAGGGCGGCGAGGGCGCAGGGAAGAAGAGGGACGTCCACTGTGGAACATGAAGCAGCATGACTGAGAAAATGTCCAGCTTCCTCTACATA GGGGACATCGTGTCCCTGTACGCGGAGGGCTCGGTCAACGGCTTCATCAGCACCTTGGGGTTAGTGGATGACAGATGTGTGGTGCACCCA GAGGCCGGGGACCTTGCCAACCCTCCCAAGAAGTTCAGAGACTGCCTTTTCAAGGTGTGCCCTATGAACAGATATTCTGCCCAGAAGCAA TATTGGAAAGCAAAGCAAGCCAAACAAGGGAACCACACCGAGGCAGCCTTGCTGAAGAAACTACAGCACGCTGCAGAACTGGAACAAAAA CAAAATGAATCGGAGAATAAGAAACTGTTGGGAGAAATTGTAAAATACAGTAATGTTATACAACTACTGCATATAAAAAGCAACAAATAT CTTACTGTCAACAAGAGATTACCTGCTTTACTGGAGAAGAATGCCATGCGTGTGTCCTTGGATGCTGCAGGAAATGAAGGGTCTTGGTTT TATATTCATCCGTTCTGGAAACTGAGAAGCGAGGGTGACAATATTGTTGTAGGAGATAAAGTTGTTTTGATGCCTGTGAATGCAGGGCAG CCACTACATGCCAGCAACATAGAGCTTCTTGATAACCCAGGGTGTAAAGAGGTGAATGCTGTCAATTGCAACACCAGCTGGAAAATCACT TTATTCATGAAATATAGTTCCTATCGAGAGGATGTATTAAAAGGAGGGGACGTTGTTAGATTATTTCATGCGGAACAAGAGAAGTTTTTG ACTTGTGATGAATATGAGAAAAAACAGCACATTTTCCTTCGTACGACCTTGCGCCAATCAGCTACTTCTGCTACTAGTTCTAAAGCACTC TGGGAAATAGAGGTGGTTCATCATGACCCATGCCGTGGGGGTGCAGGACAGTGGAACAGCTTGTTCAGATTTAAGCATCTTGCAACTGGA AACTATTTAGCTGCAGAGCTTAATCCTGATTATCGAGATGCCCAAAATGAAGGAAAAAATGTGAGAGATGGAGTCCCTCCAACTTCAAAG AAAAAACGCCAGGCAGGGGAGAAGATCATGTATACTTTGGTTTCAGTCCCGCATGGCAATGACATTGCATCCCTTTTTGAACTAGATGCC ACAACTCTTCAGAGAGCTGACTGCCTGGTTCCAAGGAACTCATATGTTCGGTTAAGGCATTTATGCACCAACACATGGGTAACCAGTACT AGTATCCCCATAGACACAGATGAAGAGAGGCCTGTTATGTTAAAGATTGGAACCTGCCAAACCAAAGAAGATAAAGAAGCGTTCGCAATC GTGTCTGTTCCACTGTCTGAAGTTCGAGACTTAGACTTTGCCAATGATGCCAATAAAGTACTAGCGACCACAGTTAAAAAGCTAGAAAAC GGCACAATAACTCAGAATGAAAGGAGGTTTGTAACCAAATTATTGGAAGATCTCATATTCTTTGTTGCTGATGTGCCTAATAATGGACAA GAAGTTCTGGATGTGGTTATCACTAAGCCAAACCGAGAGCGTCAAAAATTGATGAGGGAACAAAACATACTGGCACAGGTATTTGGAATT CTTAAAGCACCCTTTAAAGAGAAAGCAGGAGAAGGCTCGATGCTGAGACTTGAAGATCTGGGGGATCAAAGATATGCACCCTACAAGTAC ATGCTGCGGCTCTGTTACCGCGTCCTGAGACACTCGCAGCAGGATTACCGGAAAAATCAGGAATATATTGCTAAGAATTTCTGTGTCATG CAGTCCCAGATTGGCTATGATATTTTGGCAGAAGATACTATCACAGCTTTGTTGCACAACAACAGAAAACTACTAGAGAAACATATCACA GCAAAAGAAATAGAAACATTTGTCAGTTTACTCAGGAGAAATCGGGAGCCAAGGTTTTTGGATTATTTGTCAGATCTGTGTGTGTCTAAT ACCACTGCTATCCCTGTAACTCAAGAACTCATCTGTAAATTTATGTTGAGTCCAGGCAATGCAGACATTCTCATTCAAACTAAGGTGGTC TCAATGCAAGCAGACAACCCCATGGAGAGCTCCATCCTTTCAGATGACATTGATGATGAAGAAGTTTGGCTCTATTGGATTGACAGCAAC AAGGAACCTCATGGCAAAGCTATCAGGCACCTTGCTCAAGAGGCAAAAGAAGGCACCAAAGCTGACTTAGAAGTTCTTACCTATTACAGG TACCAGCTAAACCTCTTTGCAAGGATGTGCTTGGATCGCCAGTATCTGGCCATAAACCAGATTTCTACACAGCTGTCTGTAGACCTGATC CTGCGGTGTGTGTCGGATGAGAGCCTGCCGTTCGACCTCCGAGCGTCCTTCTGTCGCCTCATGCTCCACATGCACGTTGACCGGGATCCC CAGGAGTCCGTGGTGCCTGTTCGCTATGCCAGGCTCTGGACAGAAATCCCCACAAAGATCACAATTCATGAATATGATTCTATAACAGAC TCTTCCAGAAATGATATGAAGAGGAAATTTGCCCTGACAATGGAATTTGTTGAAGAATATTTGAAAGAAGTTGTAAACCAGCCCTTTCCT TTTGGGGATAAAGAAAAAAATAAACTGACATTTGAGGTGGTCCACTTGGCTCGGAATCTTATATACTTTGGATTTTATAGTTTCAGTGAG TTATTAAGGCTAACAAGAACACTTCTGGCTATTTTAGACATTGTACAGGCCCCCATGTCATCATACTTTGAAAGATTAAGCAAATTTCAA GATGGAGGAAACAATGTGATGAGAACCATTCATGGGGTGGGAGAGATGATGACCCAGATGGTACTCAGTAGAGGCTCCATCTTCCCCATG AGCGTGCCGGATGTGCCACCCAGCATCCACCCGAGCAAGCAAGGGAGCCCCACCGAGCACGAGGATGTGACTGTGATGGACACCAAGCTG AAGATCATTGAGATTTTGCAGTTTATCCTGAGTGTCAGACTGGATTATAGGATCTCATATATGCTGTCAATATATAAGAAGGAGTTTGGA GAGGACAATGACAATGCGGAGACATCTGCCAGTGGATCTCCAGACACTTTACTACCATCAGCTATTGTTCCTGATATAGATGAAATTGCA GCTCAGGCAGAAACTATGTTTGCGGGAAGAAAAGAAAAAAATCCAGTTCAACTTGACGATGAAGGAGGCAGGACGTTTTTACGGGTCCTC ATTCATCTGATCATGCACGACTACCCGCCTTTGCTGTCTGGAGCCCTGCAGCTGTTGTTTAAGCACTTCAGCCAGAGGGCAGAGGTTTTA CAGGCATTTAAGCAGGTGCAATTACTGGTGTCTAATCAAGACGTAGATAACTACAAGCAAATCAAGGCAGATCTAGACCAGCTTCGACTG ACAGTAGAAAAGTCTGAGCTATGGGTGGAGAAGAGCAGCAACTATGAGAATGGAGAAATAGGGGAAAGTCAAGTGAAAGGTGGTGAAGAG CCAATTGAGGAATCAAACATTTTAAGTCCAGTGCAGGATGGAACAAAGAAACCTCAGATTGACAGCAACAAGAGCAATAACTACCGGATT GTAAAGGAGATTTTGATCAGGCTAAGTAAACTCTGTGTGCAGAATAAAAAGTGTCGGAATCAACATCAACGATTACTGAAAAATATGGGG GCGCATTCGGTGGTGTTGGATCTTCTGCAGATACCCTATGAAAAGAATGATGAAAAGATGAATGAAGTAATGAATCTAGCCCATACATTT CTGCAGAATTTCTGTCGAGGAAATCCACAGAATCAAGTTCTTCTTCATAAACATCTGAATTTGTTTTTAACTCCAGGTCTCCTTGAAGCA GAAACCATGCGGCACATCTTCATGAACAATTACCATCTGTGCAACGAAATTAGCGAGAGAGTTGTACAACACTTTGTGCACTGCATTGAG ACACATGGCCGCCACGTGGAGTACCTGAGGTTTTTGCAAACAATTGTAAAAGCAGATGGTAAATATGTGAAGAAATGCCAGGATATGGTA ATGACAGAGTTGATAAATGGGGGTGAAGACGTGCTGATATTTTACAATGATAGAGCATCATTTCCAATCCTTCTCCATATGATGTGTTCA GAGAGAGACCGAGGGGATGAGAGTGGCCCCTTAGCCTACCACATCACCCTGGTGGAGTTGCTGGCAGCATGCACAGAGGGGAAAAATGTC TACACTGAAATCAAGTGTAATTCCCTTCTCCCGCTGGACGACATAGTGAGGGTGGTGACCCATGACGACTGCATCCCTGAGGTTAAAATT GCTTATGTGAACTTTGTTAATCACTGTTATGTTGACACTGAAGTGGAAATGAAAGAAATCTATACAAGTAACCACATTTGGAAATTATTT GAGAACTTCTTGGTGGATATGGCAAGGGTTTGCAACACAACTACAGACAGGAAACATGCAGACATCTTTTTGGAAAAGTGTGTTACTGAG TCAATAATGAATATTGTGAGCGGCTTCTTTAATTCTCCCTTTTCAGACAATAGTACCAGCCTCCAGACACATCAGCCAGTTTTTATTCAG CTACTGCAATCTGCCTTCAGAATTTACAATTGCACCTGGCCAAACCCAGCGCAGAAAGCCTCAGTGGAATCCTGTATCAGAACTTTGGCT GAAGTGGCAAAAAATCGTGGAATTGCCATTCCAGTGGATTTGGACAGCCAAGTTAATACTCTTTTCATGAAGAGCCATTCAAATATGGTG CAGAGAGCAGCAATGGGTTGGAGACTATCAGCTCGCTCTGGGCCACGCTTTAAGGAAGCTCTTGGAGGGCCTGCTTGGGATTACAGAAAT ATTATTGAAAAGTTACAGGATGTAGTGGCCTCCTTGGAGCACCAGTTCAGCCCAATGATGCAGGCTGAATTCTCAGTGTTGGTTGATGTA TTGTACAGTCCAGAACTGCTGTTCCCTGAGGGAAGCGATGCAAGAATAAGATGTGGCGCTTTCATGTCGAAGTTGATTAATCATACAAAG AAACTAATGGAGAAAGAAGAAAAACTGTGCATTAAAATTCTTCAGACATTACGAGAAATGTTAGAGAAGAAAGACAGCTTTGTGGAAGAG GATTCCTACAGGAAGCAAGTAGTAATTGATGGAGAAACCTGTCTCTTGGATATTCTCGACACAGCAGGTCAAGAGGAGTACAGTGCAATG AGGGACCAGTACATGAGGACTGGGGAGGGCTTTCTTTGTGTATTTGCCATAAATAATACTAAATCATTTGAAGATATTCACCATTATAGA GAACAAATTAAAAGAGTTAAGGACTCTGAAGATGTACCTATGGTCCTAGTAGGAAATAAATGTGATTTGCCTTCTAGAACAGTAGACACA AAACAGGCTCAGGACTTAGCAAGAAGTTATGGAATTCCTTTTATTGAAACATCAGCAAAGACAAGACAGGGTGTTGATGATGCCTTCTAT ACATTAGTTCGAGAAATTCGAAAACATAAAGAAAAGATGAGCAAAGATGGTAAAAAGAAGAAAAAGAAGTCAAAGACAAAGTGTGTAATT ATGTAAATACAATTTGTACTTTTTTCTTAAGGCATACTAGTACAAGTGGTAATTTTTGTACATTACACTAAATTATTAGCATTTGTTTTA GCATTACCTAATTTTTTTCCTGCTCCATGCAGACTGTTAGCTTTTACCTTAAATGCTTATTTTAAAATGACAGTGGAAGTTTTTTTTTCC TCTAAGTGCCAGTATTCCCAGAGTTTTGGTTTTTGAACTAGCAATGCCTGTGAAAAAGAAACTGAATACCTAAGATTTCTGTCTTGGGGC TTTTGGTGCATGCAGTTGATTACTTCTTATTTTTCTTACCAATTGTGAATGTTGGTGTGAAACAAATTAATGAAGCTTTTGAATCATCCC TATTCTGTGTTTTATCTAGTCACATAAATGGATTAATTACTAATTTCAGTTGAGACCTTCTAATTGGTTTTTACTGAAACATTGAGGGAA CACAAATTTATGGGCTTCCTGATGATGATTCTTCTAGGCATCATGTCCTATAGTTTGTCATCCCTGATGAATGTAAAGTTACACTGTTCA CAAAGGTTTTGTCTCCTTTCCACTGCTATTAGTCATGGTCACTCTCCCCAAAATATTATATTTTTTCTATAAAAAGAAAAAAATGGAAAA AAATTACAAGGCAATGGAAACTATTATAAGGCCATTTCCTTTTCACATTAGATAAATTACTATAAAGACTCCTAATAGCTTTTCCTGTTA AGGCAGACCCAGTATGAAATGGGGATTATTATAGCAACCATTTTGGGGCTATATTTACATGCTACTAAATTTTTATAATAATTGAAAAGA TTTTAACAAGTATAAAAAATTCTCATAGGAATTAAATGTAGTCTCCCTGTGTCAGACTGCTCTTTCATAGTATAACTTTAAATCTTTTCT TCAACTTGAGTCTTTGAAGATAGTTTTAATTCTGCTTGTGACATTAAAAGATTATTTGGGCCAGTTATAGCTTATTAGGTGTTGAAGAGA CCAAGGTTGCAAGGCCAGGCCCTGTGTGAACCTTTGAGCTTTCATAGAGAGTTTCACAGCATGGACTGTGTCCCCACGGTCATCCAGTGT TGTCATGCATTGGTTAGTCAAAATGGGGAGGGACTAGGGCAGTTTGGATAGCTCAACAAGATACAATCTCACTCTGTGGTGGTCCTGCTG ACAAATCAAGAGCATTGCTTTTGTTTCTTAAGAAAACAAACTCTTTTTTAAAAATTACTTTTAAATATTAACTCAAAAGTTGAGATTTTG GGGTGGTGGTGTGCCAAGACATTAATTTTTTTTTTAAACAATGAAGTGAAAAAGTTTTACAATCTCTAGGTTTGGCTAGTTCTCTTAACA CTGGTTAAATTAACATTGCATAAACACTTTTCAAGTCTGATCCATATTTAATAATGCTTTAAAATAAAAATAAAAACAATCCTTTTGATA AATTTAAAATGTTACTTATTTTAAAATAAATGAAGTGAGATGGCATGGTGAGGTGAAAGTATCACTGGACTAGGAAGAAGGTGACTTAGG TTCTAGATAGGTGTCTTTTAGGACTCTGATTTTGAGGACATCACTTACTATCCATTTCTTCATGTTAAAAGAAGTCATCTCAAACTCTTA GTTTTTTTTTTTTACAACTATGTAATTTATATTCCATTTACATAAGGATACACTTATTTGTCAAGCTCAGCACAATCTGTAAATTTTTAA CCTATGTTACACCATCTTCAGTGCCAGTCTTGGGCAAAATTGTGCAAGAGGTGAAGTTTATATTTGAATATCCATTCTCGTTTTAGGACT CTTCTTCCATATTAGTGTCATCTTGCCTCCCTACCTTCCACATGCCCCATGACTTGATGCAGTTTTAATACTTGTAATTCCCCTAACCAT AAGATTTACTGCTGCTGTGGATATCTCCATGAAGTTTTCCCACTGAGTCACATCAGAAATGCCCTACATCTTATTTCCTCAGGGCTCAAG AGAATCTGACAGATACCATAAAGGGATTTGACCTAATCACTAATTTTCAGGTGGTGGCTGATGCTTTGAACATCTCTTTGCTGCCCAATC CATTAGCGACAGTAGGATTTTTCAAACCTGGTATGAATAGACAGAACCCTATCCAGTGGAAGGAGAATTTAATAAAGATAGTGCTGAAAG AATTCCTTAGGTAATCTATAACTAGGACTACTCCTGGTAACAGTAATACATTCCATTGTTTTAGTAACCAGAAATCTTCATGCAATGAAA AATACTTTAATTCATGAAGCTTACTTTTTTTTTTTGGTGTCAGAGTCTCGCTCTTGTCACCCAGGCTGGAATGCAGTGGCGCCATCTCAG CTCACTGCAACCTCCATCTCCCAGGTTCAAGCGATTCTCGTGCCTCGGCCTCCTGAGTAGCTGGGATTACAGGCGTGTGCCACTACACTC AACTAATTTTTGTATTTTTAGGAGAGACGGGGTTTCACCCTGTTGGCCAGGCTGGTCTCGAACTCCTGACCTCAAGTGATTCACCCACCT TGGCCTCATAAACCTGTTTTGCAGAACTCATTTATTCAGCAAATATTTATTGAGTGCCTACCAGATGCCAGTCACCACACAAGGCACTGG GTATATGGTATCCCCAAACAAGAGACATAATCCCGGTCCTTAGGTAGTGCTAGTGTGGTCTGTAATATCTTACTAAGGCCTTTGGTATAC GACCCAGAGATAACACGATGCGTATTTTAGTTTTGCAAAGAAGGGGTTTGGTCTCTGTGCCAGCTCTATAATTGTTTTGCTACGATTCCA CTGAAACTCTTCGATCAAGCTACTTTATGTAAATCACTTCATTGTTTTAAAGGAATAAACTTGATTATATTGTTTTTTTATTTGGCATAA CTGTGATTCTTTTAGGACAATTACTGTACACATTAAGGTGTATGTCAGATATTCATATTGACCCAAATGTGTAATATTCCAGTTTTCTCT GCATAAGTAATTAAAATATACTTAAAAATTAATAGTTTTATCTGGGTACAAATAAACAGGTGCCTGAACTAGTTCACAGACAAGGAAACT TCTATGTAAAAATCACTATGATTTCTGAATTGCTATGTGAAACTACAGATCTTTGGAACACTGTTTAGGTAGGGTGTTAAGACTTACACA GTACCTCGTTTCTACACAGAGAAAGAAATGGCCATACTTCAGGAACTGCAGTGCTTATGAGGGGATATTTAGGCCTCTTGAATTTTTGAT GTAGATGGGCATTTTTTTAAGGTAGTGGTTAATTACCTTTATGTGAACTTTGAATGGTTTAACAAAAGATTTGTTTTTGTAGAGATTTTA AAGGGGGAGAATTCTAGAAATAAATGTTACCTAATTATTACAGCCTTAAAGACAAAAATCCTTGTTGAAGTTTTTTTAAAAAAAGCTAAA TTACATAGACTTAGGCATTAACATGTTTGTGGAAGAATATAGCAGACGTATATTGTATCATTTGAGTGAATGTTCCCAAGTAGGCATTCT AGGCTCTATTTAACTGAGTCACACTGCATAGGAATTTAGAACCTAACTTTTATAGGTTATCAAAACTGTTGTCACCATTGCACAATTTTG TCCTAATATATACATAGAAACTTTGTGGGGCATGTTAAGTTACAGTTTGCACAAGTTCATCTCATTTGTATTCCATTGATTTTTTTTTTC TTCTAAACATTTTTTCTTCAAACAGTATATAACTTTTTTTAGGGGATTTTTTTTTAGACAGCAAAAACTATCTGAAGATTTCCATTTGTC AAAAAGTAATGATTTCTTGATAATTGTGTAGTAATGTTTTTTAGAACCCAGCAGTTACCTTAAAGCTGAATTTATATTTAGTAACTTCTG TGTTAATACTGGATAGCATGAATTCTGCATTGAGAAACTGAATAGCTGTCATAAAATGAAACTTTCTTTCTAAAGAAAGATACTCACATG AGTTCTTGAAGAATAGTCATAACTAGATTAAGATCTGTGTTTTAGTTTAATAGTTTGAAGTGCCTGTTTGGGATAATGATAGGTAATTTA GATGAATTTAGGGGAAAAAAAAGTTATCTGCAGATATGTTGAGGGCCCATCTCTCCCCCCACACCCCCACAGAGCTAACTGGGTTACAGT GTTTTATCCGAAAGTTTCCAATTCCACTGTCTTGTGTTTTCATGTTGAAAATACTTTTGCATTTTTCCTTTGAGTGCCAATTTCTTACTA GTACTATTTCTTAATGTAACATGTTTACCTGGAATGTATTTTAACTATTTTTGTATAGTGTAAACTGAAACATGCACATTTTGTACATTG TGCTTTCTTTTGTGGGACATATGCAGTGTGATCCAGTTGTTTTCCATCATTTGGTTGCGCTGACCTAGGAATGTTGGTCATATCAAACAT TAAAAATGACCACTCTTTTAATTGAAATTAACTTTTAAATGTTTATAGGAGTATGTGCTGTGAAGTGATCTAAAATTTGTAATATTTTTG TCATGAACTGTACTACTCCTAATTATTGTAATGTAATAAAAATAGTTACAGTGACTATGAGTGTGTATTTATTCATGAAATTTGAACTGT TTGCCCCGAAATGGATATGGAATACTTTATAAGCCATAGACACTATAGTATACCAGTGAATCTTTTATGCAGCTTGTTAGAAGTATCCTT TATTTCTAAAAGGTGCTGTGGATATTATGTAAAGGCGTGTTTGCTTAAACTTAAAACCATATTTAGAAGTAGATGCAAAACAAATCTGCC TTTATGACAAAAAAATAGGATAACATTATTTATTTATTTCCTTTTATCAAAGAAGGTAATTGATACACAACAGGTGACTTGGTTTTAGGC CCAAAGGTAGCAGCAGCAACATTAATAATGGAAATAATTGAATAGTTAGTTATGTATGTTAATGCCAGTCACCAGCAGGCTATTTCAAGG >40702_40702_1_ITPR2-KRAS_ITPR2_chr12_26703180_ENST00000381340_KRAS_chr12_25380346_ENST00000311936_length(amino acids)=1842AA_BP=0 MTEKMSSFLYIGDIVSLYAEGSVNGFISTLGLVDDRCVVHPEAGDLANPPKKFRDCLFKVCPMNRYSAQKQYWKAKQAKQGNHTEAALLK KLQHAAELEQKQNESENKKLLGEIVKYSNVIQLLHIKSNKYLTVNKRLPALLEKNAMRVSLDAAGNEGSWFYIHPFWKLRSEGDNIVVGD KVVLMPVNAGQPLHASNIELLDNPGCKEVNAVNCNTSWKITLFMKYSSYREDVLKGGDVVRLFHAEQEKFLTCDEYEKKQHIFLRTTLRQ SATSATSSKALWEIEVVHHDPCRGGAGQWNSLFRFKHLATGNYLAAELNPDYRDAQNEGKNVRDGVPPTSKKKRQAGEKIMYTLVSVPHG NDIASLFELDATTLQRADCLVPRNSYVRLRHLCTNTWVTSTSIPIDTDEERPVMLKIGTCQTKEDKEAFAIVSVPLSEVRDLDFANDANK VLATTVKKLENGTITQNERRFVTKLLEDLIFFVADVPNNGQEVLDVVITKPNRERQKLMREQNILAQVFGILKAPFKEKAGEGSMLRLED LGDQRYAPYKYMLRLCYRVLRHSQQDYRKNQEYIAKNFCVMQSQIGYDILAEDTITALLHNNRKLLEKHITAKEIETFVSLLRRNREPRF LDYLSDLCVSNTTAIPVTQELICKFMLSPGNADILIQTKVVSMQADNPMESSILSDDIDDEEVWLYWIDSNKEPHGKAIRHLAQEAKEGT KADLEVLTYYRYQLNLFARMCLDRQYLAINQISTQLSVDLILRCVSDESLPFDLRASFCRLMLHMHVDRDPQESVVPVRYARLWTEIPTK ITIHEYDSITDSSRNDMKRKFALTMEFVEEYLKEVVNQPFPFGDKEKNKLTFEVVHLARNLIYFGFYSFSELLRLTRTLLAILDIVQAPM SSYFERLSKFQDGGNNVMRTIHGVGEMMTQMVLSRGSIFPMSVPDVPPSIHPSKQGSPTEHEDVTVMDTKLKIIEILQFILSVRLDYRIS YMLSIYKKEFGEDNDNAETSASGSPDTLLPSAIVPDIDEIAAQAETMFAGRKEKNPVQLDDEGGRTFLRVLIHLIMHDYPPLLSGALQLL FKHFSQRAEVLQAFKQVQLLVSNQDVDNYKQIKADLDQLRLTVEKSELWVEKSSNYENGEIGESQVKGGEEPIEESNILSPVQDGTKKPQ IDSNKSNNYRIVKEILIRLSKLCVQNKKCRNQHQRLLKNMGAHSVVLDLLQIPYEKNDEKMNEVMNLAHTFLQNFCRGNPQNQVLLHKHL NLFLTPGLLEAETMRHIFMNNYHLCNEISERVVQHFVHCIETHGRHVEYLRFLQTIVKADGKYVKKCQDMVMTELINGGEDVLIFYNDRA SFPILLHMMCSERDRGDESGPLAYHITLVELLAACTEGKNVYTEIKCNSLLPLDDIVRVVTHDDCIPEVKIAYVNFVNHCYVDTEVEMKE IYTSNHIWKLFENFLVDMARVCNTTTDRKHADIFLEKCVTESIMNIVSGFFNSPFSDNSTSLQTHQPVFIQLLQSAFRIYNCTWPNPAQK ASVESCIRTLAEVAKNRGIAIPVDLDSQVNTLFMKSHSNMVQRAAMGWRLSARSGPRFKEALGGPAWDYRNIIEKLQDVVASLEHQFSPM MQAEFSVLVDVLYSPELLFPEGSDARIRCGAFMSKLINHTKKLMEKEEKLCIKILQTLREMLEKKDSFVEEDSYRKQVVIDGETCLLDIL DTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSA -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for ITPR2-KRAS |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for ITPR2-KRAS |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for ITPR2-KRAS |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies